Form 8-K - Current report:
SEC Accession No. 0001193125-21-361762
Filing Date
2021-12-20
Accepted
2021-12-20 08:02:00
Documents
15
Period of Report
2021-12-20
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d276755d8k.htm   iXBRL 8-K 24434
2 EX-99.1 d276755dex991.htm EX-99.1 11476
6 GRAPHIC g276755g1220070831694.jpg GRAPHIC 3070
7 GRAPHIC g276755g1220070832616.jpg GRAPHIC 29994
  Complete submission text file 0001193125-21-361762.txt   209503

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA arwr-20211220.xsd EX-101.SCH 2919
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE arwr-20211220_lab.xml EX-101.LAB 18139
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE arwr-20211220_pre.xml EX-101.PRE 11426
9 EXTRACTED XBRL INSTANCE DOCUMENT d276755d8k_htm.xml XML 3367
Mailing Address 177 E COLORADO BLVD SUITE 700 PASADENA CA 91105
Business Address 177 E COLORADO BLVD SUITE 700 PASADENA CA 91105 626-696-4702
ARROWHEAD PHARMACEUTICALS, INC. (Filer) CIK: 0000879407 (see all company filings)

EIN.: 460408024 | State of Incorp.: DE | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-38042 | Film No.: 211503688
SIC: 2834 Pharmaceutical Preparations